Insmed moves closer to $6B opportunity as PAH drug shows long-term durability

Data ReadoutpositivePositive

AI Analysis

Summary

Insmed's inhalable PAH candidate demonstrated impressive long-term durability with functional and biomarker improvements through one year of follow-up, supporting a $6B market opportunity according to Guggenheim Partners analysts.

Clinical Trial Data

Primary Endpoint

Met

Financial Highlights

Guidance

$6B opportunity

Outcome Details

Inhalable PAH candidate showed impressive long-term efficacy with functional and biomarker improvements through one year of follow-up

Importance:6/10

Sentiment:

0.75

pulmonary_arterial_hypertensioninhalable_therapylong_term_efficacybiomarker_improvements

Related Companies

$MEHA

Read the original article

Published by BioSpace on July 17, 2026 11:44 AM

Read Original